Universidad Peruana Cayetano Heredia
Tocilizumab in COVID-19: Enthusiasm vs. evidence
JavaScript is disabled for your browser. Some features of this site may not work without it.
Mostrar el registro sencillo del ítem
| dc.contributor.author | Zena-Huancas, P. | |
| dc.contributor.author | Leon-Jimenez, F. | |
| dc.contributor.author | Bryce-Alberti, M. | |
| dc.contributor.author | Portmann Baracco, Arianna Sibila | |
| dc.date.accessioned | 2021-12-12T20:24:53Z | |
| dc.date.available | 2021-12-12T20:24:53Z | |
| dc.date.issued | 2021 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12866/10191 | |
| dc.description.abstract | Based on the pathophysiological characterization of COVID-19, initial studies suggested the use of tocilizumab (TCZ), a recombinant humanized monoclonal antibody of the immunoglobulin G1 class, for management of the cytokine storm witnessed in severe cases. Thus, we decided to present a case series of 18 patients with severe COVID-19 treated with TCZ at our hospital. Our results coincide with the fact that the routine use of TCZ in severe COVID-19 is not robustly supported. We believe that the efficacy and safety of this drug and other related molecules should be validated in large randomized clinical trials | en_US |
| dc.language.iso | eng | |
| dc.publisher | Wolters Kluwer Health | |
| dc.relation.ispartofseries | Lung India | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
| dc.subject | adult | en_US |
| dc.subject | Article | en_US |
| dc.subject | C reactive protein | en_US |
| dc.subject | clinical article | en_US |
| dc.subject | clinical decision making | en_US |
| dc.subject | clinical feature | en_US |
| dc.subject | clinical trial | en_US |
| dc.subject | coronavirus disease 2019 | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | disease severity | en_US |
| dc.subject | drug efficacy | en_US |
| dc.subject | drug safety | en_US |
| dc.subject | evidence based practice | en_US |
| dc.subject | female | en_US |
| dc.subject | high flow nasal cannula therapy | en_US |
| dc.subject | human | en_US |
| dc.subject | life threat | en_US |
| dc.subject | lung embolism | en_US |
| dc.subject | male | en_US |
| dc.subject | middle aged | en_US |
| dc.subject | mortality rate | en_US |
| dc.subject | outcome assessment | en_US |
| dc.subject | pneumopericardium | en_US |
| dc.subject | randomized controlled trial (topic) | en_US |
| dc.subject | single drug dose | en_US |
| dc.subject | tocilizumab | en_US |
| dc.subject | treatment | en_US |
| dc.title | Tocilizumab in COVID-19: Enthusiasm vs. evidence | en_US |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.doi | https://doi.org/10.4103/lungindia.lungindia_766_20 | |
| dc.relation.issn | 0974-598X |
Ficheros en el ítem
| Ficheros | Tamaño | Formato | Ver |
|---|---|---|---|
|
No hay ficheros asociados a este ítem. |
|||
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos en revistas indizadas [4988]
Recuperados de bases de datos bibliográficas
Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess
